Skip to content
Search

Latest Stories

NHS supply chain appoints Richard Evans as commercial executive director

NHS supply chain appoints Richard Evans as commercial executive director
Experienced leader to drive transformation in healthcare supply chain through new NHS  appointment

NHS Supply Chain today announced the appointment of Richard Evans as its new commercial executive director.

With 20 years’ experience in procurement and commercial management across the public and private sectors, Evans will lead the continued transformation of commercial capabilities at NHS Supply Chain.


Evans will oversee the 500 strong commercial function of the organization, focusing on standardization and simplification to create value and deliver optimal supply chain solutions for patient care.

Following significant change over the past 18 months, where more than 450 colleagues from eight outsourced procurement teams were brought in-house, Evans will oversee the continued evolution of NHS Supply Chain’s operating practices to reduce complexity, grow capabilities, and employ best practices across the commercial directorate.

He joins NHS Supply Chain from an executive leadership role at global procurement and supply chain consultancy Proxima, with experience across retail, financial services, manufacturing, and pharmaceuticals.

NHS Supply Chain’s chief executive Andrew New welcomed Evans, emphasizing the importance of his appointment in delivering the organization’s ambitions, including embedding commercial excellence, driving savings, and realizing value-based procurement.

“I’m delighted to welcome Richard to our executive team," New said.

"His role is key to supporting the delivery of our ambitious strategy of growth and savings delivery, as we align to the changing needs of the NHS.”

Evans expressed his excitement to join NHS Supply Chain during a crucial period of change, stating:

“It is fantastic to join NHS Supply Chain at such an important time of change. I am excited and look forward to working with colleagues to transform NHS Supply Chain’s commercial capabilities and support the NHS and its patients by simplifying what is a complex healthcare supply chain.”

New also recognized outgoing interim commercial executive director Bilal Shaykh, who has filled the role since October 2023.

“Bilal has successfully led the commercial function through a period of extraordinary change, and I thank him for his contribution over that period,” New said.

Evans will commence his role on 29 April 2024.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less